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ABSTRACT
A seroepidemiological study was performed to evaluate immunity to diphtheria and to determine the
correlates of diphtheria toxoid antibody levels among children and adults in Israel. In total, 3185 sera
from an age-stratiﬁed sample of children and adults, obtained in 2000–2001, were tested for diphtheria
toxoid antibodies by an in-house double-antigen ELISA. A level of £0.01 IU ⁄mL (no immune protection
or seronegativity) was found in 168 (5.3%) of the 3185 subjects, 639 (20.1%) had antibody levels of 0.011–
0.099 IU ⁄mL (basic immunity or low seropositivity), and 2378 (74.7%) had antibody levels ‡0.1 IU ⁄mL
(full protection or seropositivity). Seronegativity increased signiﬁcantly in subjects aged >50 years,
reaching levels of 9.7%, 12.6% and 18.9% in the groups aged 50–54, 55–59 and >60 years, respectively
(p 0.001), with rates of basic immunity following a similar pattern. Subjects born abroad had higher
seronegativity rates than those born in Israel (7.7% vs. 4.9%; p 0.019). No difference in diphtheria toxoid
antibody levels was found according to other demographical variables, such as gender, Jewish or Arab
ethnicity, urban or rural settlements, and the subjects’ place of residence. The level of immunity to
diphtheria among children and adults in Israel was satisfactory, with the exception of individuals aged
>50 years. The risk of diphtheria outbreaks is low, but sporadic cases may occur among individuals
lacking basic immunity against the disease.
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INTRODUCTION
The introduction of vaccination programmes
against diphtheria worldwide has been effective
in the control of the disease, but the recent
outbreaks of diphtheria in the republics of the
former Soviet Union demonstrated that re-emer-
gence of diphtheria can occur when population
immunity is not maintained [1–4]. Risk-factors for
a diphtheria epidemic include the presence of
a large number of susceptible individuals (low
immunisation coverage and inappropriate pri-
mary immunisation), lack of immunity in the
elderly, socio-geographically clustered members
of communities who refuse vaccination, and
large-scale population movements [1–4]. The
diphtheria epidemics in the republics of the
former Soviet Union raised concerns regarding
the level of immunity to diphtheria in Europe,
and prompted many European countries to con-
duct seroprevalence studies.
In Israel, comprehensive childhood immunisa-
tion against diphtheria was introduced in 1951
and has been maintained with c. 90% coverage
[5]. The current vaccination schedule comprises
four doses of diphtheria toxoid (25 limit of
ﬂoculation units (Lf) each), at ages of 2, 4, 6 and
12 months, administered together with tetanus
and pertussis vaccines, and two subsequent doses
(4 Lf), at ages of 7 and 13 years in combination
with tetanus toxoid. The booster injection at the
age of 13 years was introduced in 1999. Since
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1990, male and female recruits of the Israeli
Defence Force have also received a booster vac-
cine against diphtheria, combined with tetanus
toxoid (diphtheria low dose, 2 Lf).
The incidence of diphtheria has decreased
dramatically in Israel, from 100 to 150
cases ⁄ 100 000 ⁄ year in 1951–1955 to only ﬁve
reported cases of diphtheria in the whole popu-
lation during the last two decades [5,6] (L.
Moerman, personal communication). However,
seroepidemiological studies in Israel during the
1990s showed signiﬁcant pockets of lower immu-
nity among older age groups and immigrants
from the former Soviet Union, thus increasing the
risk of re-emergence of diphtheria in Israel [7,8].
The objectives of the present study were to
provide an update of the diphtheria immune
status in a large sample of children and adults in
Israel, to determine correlates of antibody levels
to diphtheria toxoid, and to reassess the risk of
occurrence of cases of the disease.
MATERIALS AND METHODS
Study design and sampling
A cross-sectional seroprevalence study was undertaken using
stored serum samples (n = 3185) collected by the Israel Centre
for Disease Control during 2000–2001. The serum bank
comprised samples from all regions of Israel, from both males
and females, with ages ranging from 3 weeks to 79 years.
Samples from the group aged 0–18 years were residual sera
from diagnostic laboratories, while samples from the adult
population (>18 years) were residual serum samples from
routine screening tests of healthy blood donors. Both sources
excluded blood samples taken from cases with suspected
immunological disorders. Blood donations in Israel are vol-
untary. Samples were selected randomly from the serum bank
using a stratiﬁed sampling design. The target numbers of
samples were 100 per year of age for those aged 1–19 years,
200 samples for each 5-year age group up to the age of 35–
39 years, 200 samples for each 10-year age group up to the age
of 50–59 years, and 100 samples for those aged ‡60 years. All
samples were anonymised and linked, via a unique study
number, to demographical information recorded at the time of
specimen collection. Variables included patient age, gender,
town of residence, country of birth (categorised into Israel or
other countries), place of origin, as determined by the father’s
country of birth, i.e., second-generation Israeli, ‘Western’
(Europe and the Americas) or ‘Eastern’ (Africa, Asia and the
Middle East), and ethnicity (Jewish or Arab). Actual data on
ethnicity were collected only for the younger age groups (0–
18 years). Therefore, a new variable was deﬁned, i.e., ‘modi-
ﬁed ethnicity’, which was deduced from the place of residence
(coded as Jewish, Arab, or mixed). There was good agreement
between actual ethnicity and modiﬁed ethnicity when cross-
referenced in a population where the actual ethnicity was
known.
Determination of diphtheria toxoid antibody levels
Sera were stored at )20C until tested. An in-house double-
antigen ELISA (DAE) was used to determine diphtheria toxoid
antibody levels as described previously [9], with minor
modiﬁcations. Diphtheria toxoid (Statens Serum Institute,
Copenhagen, Denmark; Batch D22-1) was used for biotin
labelling and microplate coating [9]. Pre-diluted (1:20) sample
sera, standards and controls, in dilution buffer, were added to
the plates. Three two-fold serial dilutions were made for the
initial dilution of the serum samples and controls, and six two-
fold serial dilutions of the 1st International Diphtheria Anti-
toxin Reference (DI 93) Equine (0.04 IU ⁄mL) were included in
each plate. Medium- and high-level controls, consisting of
pooled human sera of 0.3 IU ⁄mL and 3 IU ⁄mL, respectively,
were included in each test. Following the detection steps, the
OD450 nm was determined with an Emax Precision Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA). Data were
transferred online to SOFTmaxPRO software (Molecular
Devices). The antibody concentration of each sample was
calculated in relation to the standard, assuming a linear
relationship between log antibody concentration and log
absorbance. The ﬁnal antibody concentration was calculated
from the weighted mean value of the three dilutions.
Immunity to diphtheria was deﬁned as: ‘no immunity or
seronegativity’, a diphtheria antibody level of £0.01 IU ⁄mL;
‘basic immunity or low seropositivity’, 0.011–0.099 IU ⁄mL; or
‘full protection or seropositivity’, ‡0.1 IU ⁄mL [10].
All assay components, toxoid coating, biotin-labelled toxoid,
horseradish peroxidase–streptavidin, standards and controls,
were calibrated and validated to the optimal concentration.
Assays were performed by two technicians who were unaware
of the subjects’ characteristics and other test results. Criteria for
approval of results required that: standard and sample curves
were linear; r2 was >0.95; at least two dilution points could be
used; standard and sample lines were parallel, with slopes <0.9
and >0.5, and with <50% difference between the sample and
reference slope; the geometric mean of the control sera did not
exceed ±2 · SD; the absorbance of the standard (highest
concentration) was >1.2 OD to guarantee a low quantiﬁcation
limit (<0.007 IU ⁄mL); and the blank was <0.1 OD. Samples
with results that did not meet these criteria were retested at a
higher dilution (1:100) or a lower dilution (1:10) as appropriate.
The validity of the DAE for detection of diphtheria
antibodies has been demonstrated by comparison with the
toxin neutralisation test on Vero cells [9]. Quality control
assurance of the performance of the DAE with the above
methodology was conducted within the framework of the
European Seroepidemiological Network (ESEN 2). A panel of
150 sera were tested as above, and then independently by two
reference laboratories: (i) National Public Health Institute,
Helsinki, Finland, by DAE and toxin neutralisation test on
Vero cells; and (ii) Istituto Superiore di Santia, Rome, Italy, by
the double-antigen delayed time-resolved ﬂuorescence immu-
noassay (DA-DELFIA). The 150-serum panel comprised 37
samples negative for diphtheria toxoid antibodies
(£0.01 IU ⁄mL), 45 equivocal samples (0.011–0.099 IU ⁄mL),
and 68 positive samples (‡0.1 IU ⁄mL).
Statistical analysis
Prevalence rates, geometric mean concentrations (GMCs) and
95% CIs were calculated. Age- and gender-standardised
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seroprevalence estimates were also computed using the direct
method, with the total Israeli population, according to the
Statistical Abstracts of Israel 2000 [11], taken as the reference
population. Chi-square or Fisher’s exact tests were used to
analyse the association of the various demographical correlates
with the prevalence rate of diphtheria toxoid antibodies, while
differences in GMCs of diphtheria toxoid antibodies between
groups were tested for statistical signiﬁcance by Student’s
t-test. Data were analysed using SPSS v.11.5 software (SPSS
Inc., Chicago, IL, USA).
RESULTS
The mean age of the 3185 subjects tested for
diphtheria toxoid antibodies was 21 ± 16.67 years
(range 3 weeks to 79 years), with 47.3% females;
89.1% of all subjects were Jews, and 86.6% were
born in Israel. Based on the father’s country of
birth, the majority (47.7%) were second-genera-
tion Israelis, 29.7% were of Western origin, and
22.67% were of Eastern origin.
A diphtheria anti-toxoid level of £0.01 IU ⁄mL
(no immune protection or seronegativity) was
found in 168 (5.3%) of the 3185 subjects, while 639
(20.1%) had anti-toxoid levels of 0.011–
0.099 IU ⁄mL (basic immunity or low seropositiv-
ity) and 2378 (74.7%) had anti-toxoid levels
‡0.1 IU ⁄mL (full protection or seropositivity).
The age- and gender-standardised rates for no
immune protection, basic immunity and full
protection were 7.0%, 22.3% and 70.7%, respect-
ively.
Seronegativity rates increased signiﬁcantly in
subjects aged >50 years, reaching levels of 9.7%,
12.6% and 18.9% in the groups aged 50–54, 55–59
and >60 years, respectively (p 0.01; Fig. 1). The
seronegativity rates decreased signiﬁcantly in the
groups aged 10–14 years (p 0.0001) and 20–
24 years (p 0.0128) following the booster vaccin-
ation of all the population at the age of 7 years,
and of male and female subjects recruited to
military service after the age of 18 years (Fig. 1).
The rates of basic immunity (0.011–0.099 IU ⁄mL)
followed the same pattern described above. The
age groups with the highest seronegativity rates
were also those with the lowest GMC of diph-
theria toxoid antibodies measured among subjects
with antibody levels of ‡0.1 IU ⁄mL (Fig. 2).
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Fig. 1. Percentage of subjects with
diphtheria toxoid antibody levels
£0.01 IU ⁄mL (seronegative). Vertical
bars indicate 95% CIs.
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Fig. 2. Geometric mean concentra-
tion of diphtheria toxoid antibodies
among subjects with individual
antibody levels >0.01 IU ⁄mL. Verti-
cal bars indicate 95% CIs.
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Subjects born abroad had higher seronegativity
rates than those born in Israel (7.7% vs. 4.9%,
respectively; p 0.07; Table 1). When analysed
separately, the same trend of association was
found for both children and adults, but statisti-
cally signiﬁcant differences were observed only
for adults (8.4% (24 ⁄ 287) for those born abroad
vs. 4.9% (54 ⁄ 1108) for those born in Israel; p 0.03).
No statistically signiﬁcant differences in the sero-
negativity rates of diphtheria toxoid antibodies
were found according to gender, between Jewish
and Arab subjects, between urban and rural
settlements, or according to the subjects’ area of
residence (Table 1).
DISCUSSION
The diphtheria toxoid antibody levels were exam-
ined in the present study using the double-
antigen ELISA, a recently developed in-vitro
method that shows good correlation with the
toxin neutralisation test performed on Vero cells
[9]. Overall, 5.3% (range 0–18.9%) of the study
population had an antibody level £0.01 IU ⁄mL
(no immune protection to diphtheria), while
20.1% had antibody levels of 0.011–0.099 IU ⁄mL
(basic immunity or low seropositivity), and 74.7%
had antibody levels ‡0.1 IU ⁄mL (full protection
or seropositivity). The age- and gender-standard-
ised rates for the corresponding levels of immu-
nity were similar to the crude rates, thereby
demonstrating a good representation of the gen-
eral population of Israel in terms of age and
gender.
The gradual increase in seronegativity rates
with age, together with the lowest GMC of
diphtheria toxoid antibodies being found among
subjects with anti-toxoid levels >0.01 IU ⁄mL in
these age groups, reﬂect waning immunity fol-
lowing childhood vaccination without repeated
booster vaccinations in adults. A previous study
of a random sample of male Israeli reserve
soldiers serving in 1983 showed a similar increase
in seronegativity with age, with statistically sig-
niﬁcant differences between the groups aged 25–
35 years and 41–51 years [7]. Similar trends in
immunity to diphtheria have been reported from
European countries and the USA [12,13]. Decreas-
ing immunity with age among adults has been
observed in almost all studies, regardless of the
variation in testing procedures, the differences in
vaccination and booster schedules, and the ana-
lysis methods. However, the seronegativity rates
detected among adults aged >50 years in the
present study (range 9.7–18.9%) were lower than
those identiﬁed in the same age groups in various
other European countries participating in the
European Seroepidemiological Network Project
no. 1 (seronegativity rates of c. 22–50%) [12]. This
difference could be associated, at least in part,
with the nature of the adult volunteers in the
present study (i.e., blood donors), who might
have complied better with vaccination schedules
in the past.
The booster injection of diptheria toxoid given
after the age of 18 years, which is the time of
recruitment to the army for both males and
females, is most probably associated with the
decrease in the seronegativity rates seen in the
groups aged 20–24 years and 25–29 years,
respectively. For the groups aged >18 years,
blood donors were the source of the sera exam-
ined. Many blood donors among the young adult
age groups are soldiers serving in the Israel
Defence Force, with far fewer Arab and orthodox
Jewish citizens than their respective proportions
in the total Israeli population. It is therefore
possible that the observed reduction in the sero-
negativity rate for the group aged 20–24 years
would not be found in these sub-populations that
do not serve in the army. It has been shown that
the seronegativity rates in adults of countries with
compulsory military service are lower than in
Table 1. Correlates of diphtheria toxoid antibody sero-
negativity
Total tested
Seronegative to
diphtheria
pn %
Gender
Male 1679 89 5.3 0.94
Female 1506 79 5.2
Country of birth
Israel 2758 135 4.9 0.02
Other countries 427 33 7.7
Country of origin
Israel 1075 49 4.6 0.09
Eastern 508 28 5.5
Western 669 47 7.0
Ethnicitya
Jewish 2798 146 5.3 0.95
Non-Jewish 342 18 5.2
Area of residence
North Israel 908 36 4.0 0.13
Central Israel 1731 97 5.6
South Israel 534 32 6.0
Type of settlement
Urban 2691 138 5.1 0.64
Rural 449 26 5.8
aModiﬁed ethnicity (see deﬁnition in Materials and Methods).
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countries with no vaccination programmes for
adults [12]. In countries with compulsory military
service for men, but not for women, the gender-
related differences in the proportion of seroneg-
atives have been attributed to the additional
booster dose of diphtheria vaccine given to men
following their induction to the army [12]. In
Israel, large numbers of young women are con-
scripted to military service and are also given a
booster dose of diptheria vaccine. This probably
explains why no signiﬁcant gender-related differ-
ence in the proportion of subjects without basic
immunity to diphtheria was found among adults.
Most of the Arab population and part of the
orthodox Jewish religious community do not
serve in the army and therefore do not receive
the booster injection given to recruits since 1990.
To ensure a good level of immunity to diphtheria
in all Israeli young adults, an additional dose of
diphtheria vaccine has been given since 1999 to all
adolescents in Israel at the age of 13 years. This
booster injection, coupled with that given to
military recruits, will probably lead to a further
reduction in the seronegativity rate and an
increase in the proportion of the population with
full protection against diphtheria.
Subjects born abroad had higher seronegativity
rates than those born in Israel. This could be the
result of lower immunisation coverage in child-
hood, different paediatric vaccination pro-
grammes, an inferior quality of vaccine, or lack
of repetitive booster injections in the countries of
birth. No signiﬁcant differences in immunity to
diphtheria were detected among different sub-
groups, e.g., Jewish and Arab subjects, subjects
living in urban or rural settlements, and subjects
living in different areas of the country.
In the last two decades, three sporadic cases of
culture-proven diphtheria have been documented
in Israel, in 1988, 1996 and 1999, respectively [6].
All three patients were children, aged 4.5, 6 and
10 years, respectively, who belonged to orthodox
families and who did not receive diphtheria
vaccine. The two younger patients died, despite
antibiotic and supportive treatment [6]. In two of
the three cases, carriers of toxigenic Corynebacte-
rium diphtheriae were detected among asympto-
matic contacts. Two additional cases of diphtheria
have been identiﬁed, the ﬁrst in 1999, in a subject
aged 18 years with a full history of vaccination
against diphtheria but suffering from severe
cystic ﬁbrosis, and the second in 2002, in a male
aged 54 years with an unknown vaccination
history (L. Moerman, personal communication).
The occurrence of sporadic cases of diphtheria
every few years, as well as the presence of
asymptomatic carriers of toxigenic C. diphtheriae,
demonstrates that toxigenic strains of C. diphthe-
riae are still present and circulating in Israel.
Subjects with complete lack of immune protection
to diphtheria will remain at risk of developing the
disease when exposed to C. diphtheriae. The risk of
the introduction of cases of disease or healthy
carriers of toxigenic C. diphtheriae to Israel will
increase as susceptible individuals travel to
endemic areas.
Based on the ﬁndings of this study, the level of
immunity to diphtheria in the Israeli population
is probably sufﬁcient to prevent outbreaks of the
disease occurring following sporadic cases of
disease. Although the proportion of subjects
lacking basic immunity to diphtheria increases
after the age of 50 years and reaches 18.9%, this
proportion is lower than that detected in similar
serosurveys in other European countries [12].
Despite the high rates of adult susceptibility, no
sustained chains of transmission occurred in these
countries following documented importations of
cases of diphtheria [12–14]. During the large
diphtheria epidemic in Russia between 1990 and
1998, more than 10 million individuals travelled
between Finland and Russia, or vice versa. This
resulted in only ten imported cases of diphtheria
in Finland, with no secondary spread to health-
care workers or other close contacts [14].
Between 1989 and 1994, c. 600 000 immigrants
from the former Soviet Union arrived in Israel.
Immunity against diphtheria was assessed in a
sample of 992 males aged 17–49 years [8]. The
seronegativity rate in the group aged 35–49 years
was 18.2%, much higher than the overall rate of
5.3% in the present study. The difference between
the seronegativity rates of the two populations
could be even greater, since the indirect ELISA
used to examine the levels of diphtheria antibodies
among immigrants from the former Soviet Union
is known to generate more false-positive values
around the low concentration of 0.01 IU ⁄mL. Only
9% of the immigrants from the former Soviet
Union had diphtheria antibody levels >0.1 IU ⁄mL,
compared with 64.3% of the blood donors in the
present study. The different nature of the two
study populations (immigrants vs. blood donors)
could also contribute to the differences in the level
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of diphtheria toxoid antibodies. Despite the large
pockets of susceptibility in the immigrant popu-
lation from the former Soviet Union, and the
possibility that toxigenic C. diphtheriae strains from
the countries of origin were introduced into Israel,
no cases of diphtheria were identiﬁed among the
new immigrants. None of the ﬁve reported spor-
adic cases of diphtheria had an obvious link to
new immigrants from the former Soviet Union.
For many close-contact infections, including
diphtheria, the transmission potential among
children is the most important determinant of
the overall rate of transmission caused by day-
care and school-related mixing patterns [12]. The
number of susceptible children is likely to be a
critical determinant of the epidemic potential. The
level of immunity among children (age group 0–
14 years) in the present study was high (95%),
and it is assumed that this provides the necessary
level of herd immunity to prevent epidemic
transmission of C. diphtheriae if sporadic cases of
disease occur. The three cases of diphtheria that
occurred among unvaccinated subjects during the
last two decades were not followed by secondary
cases of disease [6]. The preventive measures
adopted in all these events were prompt and
adequate, but the level of protective immunity of
the population against diphtheria probably also
had a critical role in preventing further transmis-
sion of the pathogen.
In conclusion, the data generated by the present
serosurvey revealed a satisfactory level of immu-
nity to diphtheria among children and adults in
Israel, with the exception of individuals aged
>50 years, for whom the seronegativity rates
increase continuously with age. The risk of diph-
theria outbreaks is low, but sporadic cases may
occur. Active immunisation remains the most
important means of prevention of both outbreaks
and sporadic cases. Improved vaccine coverage of
travellers to endemic or epidemic areas, as well as
the recommendation of administration of a boos-
ter dose of vaccine to adults every 10 years,
should be implemented.
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